You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 11, 2025

Details for New Drug Application (NDA): 210833

✉ Email this page to a colleague

NDA 210833 describes SYMPAZAN, which is a drug marketed by Assertio Speclty and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the SYMPAZAN profile page.

The generic ingredient in SYMPAZAN is clobazam. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the clobazam profile page.

Summary for 210833

Tradename:	SYMPAZAN
Applicant:	Assertio Speclty
Ingredient:	clobazam
Patents:	3

Pharmacology for NDA: 210833

Mechanism of Action	Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inducers

Suppliers and Packaging for NDA: 210833

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SYMPAZAN	clobazam	FILM;ORAL	210833	NDA	Aquestive Therapeutics	10094-205	10094-205-60	60 POUCH in 1 PACKAGE (10094-205-60) / 1 FILM in 1 POUCH (10094-205-01)
SYMPAZAN	clobazam	FILM;ORAL	210833	NDA	Aquestive Therapeutics	10094-210	10094-210-60	60 POUCH in 1 PACKAGE (10094-210-60) / 1 FILM in 1 POUCH (10094-210-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	FILM;ORAL			Strength	5MG
Approval Date:	Nov 1, 2018	TE:		RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Jan 31, 2040	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	METHOD OF TREATING SEIZURES
Patent:	⤷ Get Started Free	Patent Expiration:	Sep 5, 2039	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	METHOD OF TREATING SEIZURES
Patent:	⤷ Get Started Free	Patent Expiration:	Sep 5, 2039	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	METHOD OF TREATING SEIZURES

Expired US Patents for NDA 210833

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Assertio Speclty	SYMPAZAN	clobazam	FILM;ORAL	210833-002	Nov 1, 2018	⤷ Get Started Free	⤷ Get Started Free
Assertio Speclty	SYMPAZAN	clobazam	FILM;ORAL	210833-001	Nov 1, 2018	⤷ Get Started Free	⤷ Get Started Free
Assertio Speclty	SYMPAZAN	clobazam	FILM;ORAL	210833-002	Nov 1, 2018	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.